Serious infection with tofacitinib in patients with rheumatoid arthritis: the importance of context

被引:0
作者
Rivas, Jose L. [1 ]
Jones, Thomas [2 ]
Connell, Carol A. [3 ]
机构
[1] Pfizer, Madrid 28108, Spain
[2] Pfizer, Collegeville, PA USA
[3] Pfizer, Groton, CT USA
关键词
D O I
10.1016/S2665-9913(20)30211-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:E738 / E738
页数:1
相关论文
共 3 条
[1]  
European Medicines Agency, Assessment report
[2]   Tofacitinib's infectious profile: concerns for clinical practice [J].
Favalli, Ennio Giulio .
LANCET RHEUMATOLOGY, 2020, 2 (02) :E65-E67
[3]   Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study [J].
Pawar, Ajinkya ;
Desai, Rishi J. ;
Gautam, Nileesa ;
Kim, Seoyoung C. .
LANCET RHEUMATOLOGY, 2020, 2 (02) :E84-E98